Clinical Programs

Therapix to Present at and Attend Investor Conferences in London
Presentation at the Biotech & Money Inv€$tival Showcase to Be Held on November 14, 2017 at 4:15PM CET

TEL AVIV, Israel, Nov. 7, 2017 /PRNewswire/ -- Josh Blacher, Chief Financial Officer of Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, will be presenting at the Biotech & Money Inv€$tival Showcase on November 14, 2017 and attending the Jefferies Healthcare Conferences on November 15-16, 2017, in London. In exclusive partnership with Jefferies LLC, the Inv€$tival Showcase spans four tracks and will feature the most exciting companies across seven key sub-sectors within life sciences.

  • Event:                         Biotech & Money Inv€$tival Showcase
  • Date:                           Tuesday, November 14, 2017
  • Presentation Time:     4:15PM CET
  • Location:                     The Hilton Waldorf, Aldwych, London


  • Event:                         Jefferies Healthcare Conference
  • Date:                           November 15-16, 2017
  • Location:                     The Hilton Waldorf, Aldwych, London

Mr. Blacher's presentation at the Biotech & Money Inv€$tival Showcase on November 14 will be webcast live and will remain available for 90 days following the presentation. To access the webcast, please visit the Events tab of the Investor Relations section of the Therapix website at

About Therapix Biosciences:

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-110 targets the treatment of the symptoms of Tourette syndrome; and THX-130 targets the high-value and under-served market of mild cognitive impairments and Traumatic Brain Injury (TBI).

Please visit our website for more information at

Forward-Looking Statements:

This press release contains forward-looking statements about the Company's expectations, beliefs, and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Such forward-looking statements used in this press release include, among other things, references to the clinical and commercial potential of THX-OSA01 for the treatment of Obstructive Sleep Apnea. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding needed to continue to pursue our business and product development plans, the inherent uncertainties associated with developing new products or technologies, our ability to obtain regulatory approval for our product candidates, our ability to commercialize our product candidates, competition in the industry in which we operate and overall market conditions. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Therapix Biosciences Ltd.'s annual report on Form 20-F dated May 1, 2017 filed with the SEC, which is available on the SEC's website,

For further information:

Investor Contact:
Josh Blacher
CFO, Therapix Biosciences
Therapix Biosciences Ltd.

For further information: +972-3-616-7055

Media Contact:
Susan Forman

SOURCE Therapix Biosciences Ltd.